Skip Navigation

U.S. Flag

Print Print   Download Reader Download   Text Enlarge text size Reduce text size Normal text size

Go to Text Version

HHS Recovery Act Recipient Reporting Readiness Tool

Step 4. Review and Copy the Grant Awards Data

TAGGS provides some – but not all – of the data needed for the Recipient Report. Recipients are responsible for directly collecting and reporting all required data to FederalReporting.gov. Data that HHS does not currently collect are highlighted in yellow. Do not copy this highlighted information. Please enter the appropriate data for your organization in these required fields. For assistance with entering these data please contact FederalReporting.gov.

You may capture the data HHS does provide by copying data from this screen and pasting it into the reporting format of your choice, such as the Excel spreadsheet template, the XML template, or by logging into the online form. For assistance with copying and pasting these data please e-mail our help desk at Readiness Help.

 

Award Detail for: DEVELOPMENT OF A UNIVERSAL INFLUENZA VIRUS VACCINE
MT SINAI SCHOOL OF MEDICINE
DUNS Number: 078861598
1 GUSTAVE L LEVY PL, BOX 3500
NEW YORK-NEW YORK, NY 10029-6500
Recipient Report: Grant or Loan
Prime Recipient

Reporting Information
Award Type Award Number Final Report
Grant 5RC1AI086061-02 Recipient responsible for this data

Award Recipient Information
Recipient DUNS Number Recipient Account Number Recipient Congressional District
078861598 Recipient responsible for this data 15

Award Information
Funding Agency Code Awarding Agency Code Award Date
7529 7529 08-24-2010
Amount of Award Sub Account Number for Program Source (TAS)  
$ 500,000 Recipient responsible for this data
Program Source (TAS)* CFDA Number 
750845 93.701
Total Number of Sub Awards to Individuals Total Amount of Sub Awards to Individuals
Recipient responsible for this data Recipient responsible for this data
Total Number of Payments to Vendors less than $25,000/award Total Amount of Payments to Vendors less than $25,000/award
Recipient responsible for this data Recipient responsible for this data
Total Number of Sub Awards less than $25,000/award Total Amount of Sub Awards less than $25,000/award
Recipient responsible for this data Recipient responsible for this data
Award Description
DESCRIPTION (provided by applicant): This application addresses broad challenge area (15) Translational Science and specific Challenge Topic, 15-AI-106: translational research focused on high priority pathogens and basic research focused on resistance mechanisms. The research described herein can be initiated immediately and completed within two years. The work proposed will maintain or create three full time positions and will require the purchase of products and services from the biotech industry. In the longer term, the outcome of the proposed research may stimulate the economy by greatly reducing employee absenteeism due to influenza illness and eliciting the investment of vaccine companies in the optimization and manufacture of universal influenza vaccines. Specifically, we propose the development of novel influenza vaccine constructs which have the potential to protect against a wide range of antigenically-drifted variant viruses and against multiple subtypes influenza A viruses. The design of these constructs is based on our and others' recent observations that monoclonal antibodies which bind to the conserved stalk region of the influenza A virus hemagglutinin (HA) molecule are both broadly cross-reactive and neutralizing. The identified epitope is highly conformational, comprising portions of both the HA1 and HA2 subunits, and is located in the membrane proximal region of the HA protein. During natural infection or vaccination with conventional influenza vaccines, this region of the HA molecule is thought to be masked by the membrane distal portion of HA, a bulky and highly immunogenic globular head domain. Indeed, the immune response to vaccines currently in use is predominantly targeted against the globular head of HA; since this domain is very poorly conserved, current vaccines protect only against relatively small clusters of closely related strains. We have identified a way of expressing a modified HA molecule which lacks the globular head domain and maintains the structural integrity of the stalk region. This molecule forms the basis for a new generation of influenza vaccines which will induce broadly cross- neutralizing antibodies against the conserved stalk region. Such vaccines have the potential to provide protection against epidemic strains arising over several decades, obviating the need for annual influenza vaccination. In addition, vaccines based on the conserved HA stalk domain are predicted to be effective against influenza viruses of most (perhaps all) of the 16 HA subtypes and therefore to provide protection in the event of an influenza pandemic. PUBLIC HEALTH RELEVANCE: The research we propose is aimed at developing a new influenza virus vaccine which has the potential to protect against many distinct types of influenza virus. If successful, this vaccine could protect recipients against influenza for decades, rather than for just one or two years as the current vaccines do. In addition, since it would work against a broad range of influenza viruses, it would provide protection in the event of an influenza pandemic.

Project Information
Project Name or
Project/Program Title
Project Status Total Federal Amount ARRA Funds
Received/Invoiced
DEVELOPMENT OF A UNIVERSAL INFLUENZA VIRUS VACCINE Recipient responsible for this data Recipient responsible for this data
Number of Jobs Description of Jobs Created
Recipient responsible for this data Recipient responsible for this data
Quarterly Activities/Project Description
Recipient responsible for this data
 
Activity Code (NAICS or NTEE-NPC)
1Recipient responsible for this data2Recipient responsible for this data
3Recipient responsible for this data4Recipient responsible for this data
5Recipient responsible for this data6Recipient responsible for this data
7Recipient responsible for this data8Recipient responsible for this data
9Recipient responsible for this data10Recipient responsible for this data
Total Federal Amount of ARRA
Expenditure
Total Federal ARRA
Infrastructure Expenditure
Infrastructure Contact Name
Recipient responsible for this data Recipient responsible for this data Recipient responsible for this data
Infrastructure Contact Email Infrastructure Contact Phone Infrastructure Contact Phone Ext.
Recipient responsible for this data Recipient responsible for this data Recipient responsible for this data
Infrastructure Contact Street Address 1 Infrastructure Contact Street Address 2 Infrastructure Contact Street Address 3
1 GUSTAVE L LEVY PL, BOX 3500 Not Available Recipient responsible for this data
Infrastructure City Infrastructure State Infrastructure ZIP Code+4
NEW YORK-NEW YORK NY 10029-6500
Infrastructure Purpose and Rationale
Recipient responsible for this data

Primary Place of Performance
Street Address 1 Street Address 2 City
BOX 1075 Recipient responsible for this data NEW YORK
State Zip Code+4 Congressional District
NY 10029 14
Country  
US

Recipient Highly Compensated Officers
Prime Recipient Indication of Reporting Applicability # Officer Name Officer Compensation
Recipient responsible for this data 1 Recipient responsible for this data Recipient responsible for this data
2 Recipient responsible for this data Recipient responsible for this data
3 Recipient responsible for this data Recipient responsible for this data
4 Recipient responsible for this data Recipient responsible for this data
5 Recipient responsible for this data Recipient responsible for this data

This concludes the current search.
To begin a new search, return to the HHS Recovery Act Recipient Reporting Readiness Tool.

USE IN THE RECIPIENT REPORT

The information provided by this tool is baseline data that the Recipient should include in the Recipient Report that must be submitted to FederalReporting.gov beginning October 1, 2009. The data from this tool can be cut and pasted directly into the Recipient Report.